The aim of this non-interventional (observational) study is to document, in collaboration with established urologists in Scandinavia, experience gained from routine use of Vantas® for the treatment of patients with advanced prostate cancer. In this observational study particular attention will be directed to treatment duration, quality of life and patient and physician acceptance of the medicinal product for long-term therapy. Patient-based measurement parameters such as quality of life and degree of satisfaction will allow registration of information that extends beyond the clinical parameters. The knowledge gathered will enable patient acceptance of long-term therapy to be evaluated. Clinical outcome will also be documented by measuring serum testosterone and prostate specific antigen (PSA) levels.
Study Type
OBSERVATIONAL
Enrollment
142
Urology Dep. Skane Univeristy Hospital
Malmo, Sweden
Treatment duration follow-up for each patient.
Time frame: 1 year
Blood samples
PSA and Testosterone measurement
Time frame: 1 year
Quality of Life measurements
EORTC documents
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.